A document which lays out the plans for investigating the effects of a new drug or therapy on the paediatric population (infants, children and adolescents). A PIP is mandatory when applying for first marketing authorisation of unapproved drugs, or when applying for variations in approval to cover new indications, new pharmaceutical forms of the drug, or new means of drug administration.